Huntingtin Inhibitors

Huntingtin inhibitors represent a class of chemical compounds designed to target and modulate the activity of the huntingtin protein, a key player in the pathogenesis of Huntington's disease (HD). Huntington's disease is a devastating neurodegenerative disorder characterized by progressive motor dysfunction and cognitive impairment. The disease is primarily caused by a mutation in the HTT gene, which results in the production of a mutant huntingtin protein with an expanded polyglutamine tract. This mutant protein forms toxic aggregates in neurons, leading to neuronal dysfunction and death. Huntingtin inhibitors are developed with the aim of mitigating the pathological effects of mutant huntingtin in HD. These inhibitors primarily target various aspects of huntingtin biology, including its expression, post-translational modifications, and interactions with other cellular components. One approach involves small molecules that reduce the production of mutant huntingtin by inhibiting the translation of the HTT mRNA or enhancing its degradation. Another strategy focuses on preventing the abnormal aggregation of mutant huntingtin, either by directly disrupting the aggregation process or by promoting the clearance of existing aggregates through autophagy or other cellular mechanisms. Additionally, some huntingtin inhibitors aim to modulate the interactions between mutant huntingtin and its binding partners, altering its cellular effects.